← Back
Data updated: Mar 10, 2026
HISUN PHARM HANGZHOU
CardiovascularOncologyInfectious Disease
HISUN PHARM HANGZHOU is a generic drug manufacturer focused on Cardiovascular, Oncology, Infectious Disease. Key products include DAPTOMYCIN.
2009
Since
18
Drugs
-
Trials
286
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
MICAFUNGIN SODIUM 2026-02-24
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
PRAVASTATIN SODIUM 2026-02-06
Labeling
TICAGRELOR 2026-02-06
DOXORUBICIN HYDROCHLORIDE 2026-02-03
EPIRUBICIN HYDROCHLORIDE 2026-01-30
Labeling
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
OLANZAPINE 2026-01-23
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 30%
3 drugs
Oncology 30%
3 drugs
Infectious Disease 20%
2 drugs
Neurology 10%
1 drugs
Dermatology 10%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology, Cardiovascular
Active (12)
Discontinued (6)
Company Info
- First Approval
- 2009-01-28
- Latest
- 2026-01-21
- Applications
- 21